Performing open bypass surgery treatment of choice in chronic limb-threatening ischemia

The cases of peripheral artery disease, a condition in which blood flow to one or both legs is reduced by a buildup of fatty plaque in the arteries are rising. Further about 10% of patients of PAD develop chronic limb-threatening ischemia (CLTI), a painful and debilitating condition that can lead to amputation if untreated. Up to about 22 million people worldwide have chronic limb-threatening ischemia, which is also associated with an increased risk of heart attack, stroke, and death.

Researchers have found in a National Institutes of Health-supported clinical research trial that among patients with chronic limb-threatening ischemia who had an adequate great saphenous vein for surgical revascularization Bypass surgery was a favorable treatment option compared to endovascular treatment. Further the incidence of a major adverse limb event or death was significantly lower in the surgical group than in the endovascular group.

Performing open bypass surgery to restore circulation for people with a severe form of peripheral artery disease (PAD)-a condition that limits blood flow to the legs and feet-resulted in better outcomes for specific patients compared to a less-invasive procedure, a National Institutes of Health-supported clinical research trial has found.

"Given the projected rise in the number of patients with chronic limb-threatening ischemia, it is critically important that we understand the full impact of our interventions for this disease," said Matthew Menard, M.D., a study author and associate professor of surgery and co-director of the endovascular surgery program at Brigham and Women's Hospital, Boston. "These findings help do that and also can assist clinicians and caregivers in providing the best possible care to patients."

The Best Endovascular versus Best Surgical Therapy for Patients with CLTI (BEST-CLI) trial is a landmark study supported by the National Heart, Lung, and Blood Institute (NHLBI). The findings were published in the New England Journal of Medicine and simultaneously presented as late-breaking research at the American Heart Association's Scientific Sessions 2022.

To better understand the effectiveness of two common treatments for CLTI, researchers enrolled 1,830 adults who were planning to have revascularization, a procedure used to restore blood flow in their blocked arteries, and who were eligible for both treatment strategies.

One treatment strategy was an open bypass surgery, in which blood is redirected around the blocked leg artery by using a segment of a healthy vein. The other strategy was an endovascular procedure-one performed inside the blood vessels where a balloon is dilated and/or a stent is placed in the blocked segment of the artery to improve blood flow. To compare the surgical strategy to the less-invasive endovascular approach, researchers randomized participants into one of two parallel trials conducted at 150 medical centers in the United States, Canada, Finland, Italy, and New Zealand between 2014-2021.

The first trial, defined as cohort 1, included 1,434 adults who were judged to be the best candidates for the bypass surgery because they had an adequate amount of an optimal vein (the single-segment great saphenous vein) preferred for the procedure. Participants were then randomly assigned to have either a surgical bypass or endovascular procedure. Researchers followed the trial participants for up to seven years.

The second trial, defined as cohort 2, included 396 adults who were not the best candidates for the open bypass because they did not have an adequate amount of the preferred saphenous vein. They were randomized to have either an endovascular procedure or a bypass that used alternate graft material instead of the saphenous vein. Researchers followed the trial participants for up to three years.

At the end of the trial, the researchers found that participants in cohort 1 who received the bypass were 32% less likely to have major medical events related to CLTI than those who had an endovascular procedure. This result was driven by a 65% reduction in major repeat surgeries or procedures to retain blood flow in the lower leg and a 27% reduction in major amputations. No differences were found in death rates between the participants who received the bypass surgery and those who received an endovascular procedure.

Adults in cohort 2-those who did not have the optimal vein for the bypass-had no major differences in outcomes based on having had an open bypass or an endovascular procedure.

"Our findings support complementary roles for these two treatment strategies and emphasize the need for preprocedural planning to assess patients and inform what treatment is selected," said co-principal investigator Alik Farber, M.D., chief of the Division of Vascular and Endovascular Surgery at Boston Medical Center.

"This study is a superb exemplar of how comparative effectiveness research can show us the most promising surgical interventions toward improving quality of life and long-term outcomes for those who suffer from the most severe cases of PAD," said NHLBI Director Gary H. Gibbons, M.D.

Common symptoms of CLTI include leg and foot pain, foot infections, and open sores on the leg and foot that don't fully heal. Without having a procedure to redirect or open blocked blood flow to the lower body, about 4 in 10 adults with CLTI have a lower leg or foot amputation.

BEST-CLI is the largest CLTI clinical trial to date and builds on prior research that aims to answer questions about the risks and benefits of revascularization strategies for chronic limb-threatening ischemia.

Reference:

Alik Farber, M.D., Matthew T. Menard, M.D., Michael S. Conte, M.D., John A. Kaufman, M.D., Richard J. Powell, M.D., Niteesh K. Choudhry, M.D., Ph.D., Taye H. Hamza, Ph.D., Susan F. Assmann, Ph.D., Mark A. Creager, M.D., Mark J. Cziraky, Pharm.D., Michael D. Dake, M.D., Michael R. Jaff,November 7, 2022 DOI: 10.1056/NEJMoa2207899